-
-
Phase 2/3 adaptive study design for Lupus study agreed with Avion
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market on its Lupuzor™ programme in patients with systemic lupus erythematosus (“SLE”) Key highlights: In conjunction with its partner Avion Pharmaceuticals (“Avion”), ImmuPharma confirms that a Phase 2/3 adaptive trial will be the best design for the next clinical study…
-
Grant of Share Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non Executive Directors) has determined to award Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows: Tim…
-
End of Year Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market. Review of 2022 and Outlook for 2023 As we approach the end of 2022 the Company can confirm that it continues to work proactively, together with our partner Avion Pharmaceuticals (“Avion) and external advisors, on the preparations around the…
-
Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to update the market on a recent meeting in Atlanta, USA with our US partner, Avion Pharmaceuticals, LLC (“Avion”) for strategic discussions around ImmuPharma’s Lupuzor™ clinical program. This included Avion continuing its support to the clinical program of Lupuzor™ for Lupus, as well…
-
Lupuzor™ Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update on Lupuzor™, following the Company’s recent announcement on 14 September 2022, that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. In summary, the FDA…
-
INTERIM RESULTS for the six months ended 30 June 2022
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2022 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Loss for the Period of £1.7m (30 June 2021: £3.7m)…
-
Written response received from the FDA
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that, further to the Company’s notification of 7 July 2022, its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. The FDA response was detailed and included significant…
